Watchful Waiting and Quality of Life Among Prostate Cancer Survivors in the Physicians' Health Study

Jemal, 2010, Cancer Statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322/caac.20073 Schroder, 2009, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 360, 1320, 10.1056/NEJMoa0810084 Hugosson, 2010, Mortality results from the Goteborg randomised population-based prostate-cancer screening trial, Lancet Oncol, 11, 725, 10.1016/S1470-2045(10)70146-7 Warlick, 2006, Delayed versus immediate surgical intervention and prostate cancer outcome, J Natl Cancer Inst, 98, 355, 10.1093/jnci/djj072 Klotz, 2007, Active surveillance for favorable-risk prostate cancer: who, how and why?, Nat Clin Pract Oncol, 4, 692, 10.1038/ncponc0966 Dall'Era, 2008, Active surveillance for early-stage prostate cancer: review of the current literature, Cancer, 112, 1650, 10.1002/cncr.23373 Patel, 2004, An analysis of men with clinically localized prostate cancer who deferred definitive therapy, J Urol, 171, 1520, 10.1097/01.ju.0000118224.54949.78 Shappley, 2009, Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort, J Clin Oncol, 27, 4980, 10.1200/JCO.2008.21.2613 Koppie, 2000, Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from the CaPSURE database, J Urol, 164, 81, 10.1016/S0022-5347(05)67454-X Bill-Axelson, 2005, Radical prostatectomy versus watchful waiting in early prostate cancer, N Engl J Med, 352, 1977, 10.1056/NEJMoa043739 Steineck, 2002, Quality of life after radical prostatectomy or watchful waiting, N Engl J Med, 347, 790, 10.1056/NEJMoa021483 Arredondo, 2004, Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE, J Urol, 172, 1830, 10.1097/01.ju.0000140758.04424.77 Katz, 2007, Changes in continence and health-related quality of life after curative treatment and watchful waiting of prostate cancer, Urology, 69, 1157, 10.1016/j.urology.2007.02.003 Litwin, 1995, Quality-of-life outcomes in men treated for localized prostate cancer, JAMA, 273, 129, 10.1001/jama.273.2.129 Sanda, 2008, Quality of life and satisfaction with outcome among prostate-cancer survivors, N Engl J Med, 358, 1250, 10.1056/NEJMoa074311 Hennekens, 1985, A randomized trial of aspirin and beta-carotene among U.S. physicians, Prev Med, 14, 165, 10.1016/0091-7435(85)90031-3 Sesso, 2008, Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial, JAMA, 300, 2123, 10.1001/jama.2008.600 1989, Final report on the aspirin component of the ongoing Physicians' Health Study, N Engl J Med, 321, 129, 10.1056/NEJM198907203210301 Hennekens, 1996, Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease, N Engl J Med, 334, 1145, 10.1056/NEJM199605023341801 Lubeck, 1999, Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE, Urology, 53, 180, 10.1016/S0090-4295(98)00408-7 Litwin, 1998, The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure, Med Care, 36, 1002, 10.1097/00005650-199807000-00007 Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8 Driver, 2008, Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study, Neurology, 70, 1423, 10.1212/01.wnl.0000310414.85144.ee Loeb, 2007, Prostate-specific antigen in clinical practice, Cancer Lett, 249, 30, 10.1016/j.canlet.2006.12.022 D'Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, 969, 10.1001/jama.280.11.969 Fang, 2011, Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer, PLoS One, 6, e18625, 10.1371/journal.pone.0018625 Hendrickson, 2011, Vitamin D receptor protein expression in tumor tissue and prostate cancer progression, J Clin Oncol, 29, 2378, 10.1200/JCO.2010.30.9880 Meng, 2003, Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE, J Urol, 170, 2279, 10.1097/01.ju.0000094190.46523.b2 Wu, 2004, Watchful waiting and factors predictive of secondary treatment of localized prostate cancer, J Urol, 171, 1111, 10.1097/01.ju.0000113300.74132.8b Schapira, 2001, Effect of treatment on quality of life among men with clinically localized prostate cancer, Med Care, 39, 243, 10.1097/00005650-200103000-00005